glp-1 weight-loss drugs What to Make of the Coverage and Cost Landscape Half of GLP-1 users ditch
Description
Tirzepatide has been shown in clinical trials to reduce the risk of cardiovascular events at various doses, suggesting a potential treatment option for patients who are obese or overweight [2]
Epidemiology of inflammatory bowel disease across the ages in the era of advanced therapies
Eli Lillys patents on tirzepatide dont begin to expire until 2036
Nutritional support during GLP-1 treatment cannot be overstated
2020;101(Suppl 1):13645
